Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | MPL | P40238 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31279653 | 1.00 | CA1 (0.42) | CA1CA2CA5ACA9HSD11B1 | |
| SCHEMBL396026 | 0.83 | POLB (0.44) | CA2SMN1; SMN2POLBALDH1A1TDP1 | |
| SCHEMBL30772352 | 0.80 | SMN1; SMN2 (0.37) | CA1CA2CA5ACA9HSD11B1 | |
| SCHEMBL18980143 | 0.79 | GLA (0.37) | CA1CA2CA5ACA9KDM1A | |
| SCHEMBL31448549 | 0.78 | THRA (0.42) | CA1CA2CA5ACA9HSD11B1 | |
| SCHEMBL1530406 | 0.77 | CA2 (0.44) | CA1CA2CA5ACA9ALDH1A1 | |
| SCHEMBL16414055 | 0.76 | MPL (0.44) | HSD11B1POLBALDH1A1TDP1L3MBTL1 | |
| SCHEMBL476347 | 0.76 | CD44 (0.42) | SMN1; SMN2POLBALDH1A1TDP1L3MBTL1 | |
| SCHEMBL7191759 | 0.76 | TAS2R14 (0.42) | CA1CA2CA5ACA9HSD11B1 | |
| SCHEMBL29589903 | 0.76 | CD44 (0.42) | SMN1; SMN2POLBALDH1A1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119100934-A | Preparation method of 2-amino-3-bromobenzotrifluoride | 帕潘纳(北京)科技有限公司 | 2024-12-10 | — | — | CN | claimed |
| CN-118388455-A | Thermal delay fluorescent material based on trifluoromethyl modification, preparation method and electroluminescent device | 内蒙古民族大学 | 2024-07-26 | — | — | CN | claimed |
| CN-119100934-A | Preparation method of 2-amino-3-bromobenzotrifluoride | 帕潘纳(北京)科技有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-119100934-A | Preparation method of 2-amino-3-bromobenzotrifluoride | 帕潘纳(北京)科技有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-119100934-A | Preparation method of 2-amino-3-bromobenzotrifluoride | 帕潘纳(北京)科技有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240343709-A1 | SUBSTITUTED HETEROCYCLES AS ALDEHYDE DEHYDROGENASE INHIBITORS | THE TRUSTEES OF PRINCETON UNIVERSITY | 2024-10-17 | — | — | US | disclosed |
| US-12110293-B2 | Substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2024-10-08 | — | — | US | disclosed |
| US-12054475-B2 | Substituted heterocycles as aldehyde dehydrogenase inhibitors | KAYOTHERA INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118388455-A | Thermal delay fluorescent material based on trifluoromethyl modification, preparation method and electroluminescent device | 内蒙古民族大学 | 2024-07-26 | — | — | CN | disclosed |
| CN-113651710-B | Preparation method of 3, 5-substituted-4-amino trifluoroacetophenone and derivatives thereof | 台州臻挚生物科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240132469-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KAYOTHERA INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2020016453-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2020-01-23 | — | — | WO | disclosed |
| CN-103153996-B | As quinoline and the quinoxaline derivatives of kinase inhibitor | UCB PHARMA S.A. (BE) | 2016-01-27 | — | — | CN | disclosed |
| EP-2614061-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-9029392-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2015-05-12 | — | — | US | disclosed |
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-11-07 | — | — | US | disclosed |
| EP-2614061-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012032334-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2012-03-15 | — | — | WO | disclosed |
| US-3978040-A | Process for the preparation of cyanoazo compounds by reacting halogenoazo compounds with CuCN in an aqueous media in the presence of a nitrogen base | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-31 | — | — | US | disclosed |
| US-3976633-A | ANORECTIC, ANTIOBESITY | SMITHKLINE CORPORATION (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343709-A1 | SUBSTITUTED HETEROCYCLES AS ALDEHYDE DEHYDROGENASE INHIBITORS | ALDH3A1, ALDH2, ALDH1A2 | CA1 2082/4885CA2 933/4885CA5A 138/4885 |
| US-12054475-B2 | Substituted heterocycles as aldehyde dehydrogenase inhibitors | ALDH3A1, ALDH2, ALDH1A2 | CA1 2082/4885CA2 933/4885CA5A 138/4885 |
| US-20240132469-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, ALDH2, PDK1 | CA1 2020/4885CA2 876/4885CA5A 106/4885 |
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | MAP3K13, MAP4K3, MAP3K3 | CA1 3521/4885CA2 1837/4885CA5A 2618/4885 |
| US-12110293-B2 | Substituted triazolo quinoxaline derivatives | NR3C1, NR3C2, GRK5 | CA1 3877/4885CA2 3220/4885CA5A 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.